[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362700-105":59,"doc-detail-362700-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","single-cell-transcriptomic-mapping-of-patient-derived-primary-liver-cancer-organoids-reveals-molecular-subtypes-and-guides-precision-drug-targeting","Single-cell transcriptomic mapping of patient-derived primary liver cancer organoids reveals molecular subtypes and guides precision drug targeting","","Current liver cancer research lacks reliable in vitro models that replicate tumor pathophysiology. This study establishes primary liver cancer (PLC) organoids from hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined hepatocellular-cholangiocarcinoma (CHC) to support precise diagnostics and personalized therapies through comprehensive genomic profiling. Organoid cultures from 11 patients were analyzed using WES, RNA-seq, and scRNA-seq, followed by subtype-pathway drug screening to validate findings.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/single-cell-transcriptomic-mapping-of-patient-derived-primary-liver-cancer-organoids-reveals-molecular-subtypes-and-guides-precision-drug-targeting/362700/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/single-cell-transcriptomic-mapping-of-patient-derived-primary-liver-cancer-organoids-reveals-molecular-subtypes-and-guides-precision-drug-targeting/362700.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What organoid models were established in this study?","Question",{"text":112,"@type":113},"Primary liver cancer organoids were generated from three major subtypes: HCC, ICC, and CHC, derived from 11 patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which sequencing methods were used to characterize molecular differences?",{"text":117,"@type":113},"Whole exome sequencing (WES), RNA-seq, and single-cell RNA-seq (scRNA-seq) were used to analyze genetic and cellular heterogeneity.",{"name":119,"@type":110,"acceptedAnswer":120},"How were subtype-specific drugs validated in the organoid system?",{"text":121,"@type":113},"Drug screening targeting pathways specific to each subtype was performed to confirm sequencing-based therapeutic vulnerabilities, such as rosuvastatin for HCC and pemigatinib for ICC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362700,1790890635,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cellular Oncology (2026) 49:52  \n[https://doi.org/10.1007/s13402-026-01](https://doi.org/10.1007/s13402-026-01)190-w  \nRESEARCH  \nSingle-cell transcriptomic mapping of patient-derived primary liver cancer organoids reveals molecular subtypes and guides precision drug targeting  \nShipeng Dai1 · Jian Wu2 · Yue Chai1 · Zhouxiao Li3 · Yuchen Xie1 · Hongyu Wang1 · Ziyuan Liu1 · Yanshu He1 · Hengsong Cao1 · Weiwei Tang1 · Jintao Xu4 · Zongkang Zhang4 · Yongxiang Xia1 · Xuehao Wang1 · Li Liu5,6 · Xinyi Xia7,8 · Yun Gao1  \nReceived: 27 September 2025 / Accepted: 8 March 2026 © The Author(s) 2026  \nAbstract  \nBackground Current liver cancer research lacks reliable in vitro models that replicate tumor pathophysiology. This study establishes primary liver cancer (PLC) organoids from three major subtypes—hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined hepatocellular-cholangiocarcinoma (CHC)—to enable precise diagnostics and personalized therapies through comprehensive genomic profiling.  \nMethods Organoid cultures were generated from 11 PLC patients (5 HCC, 3 ICC, 3 CHC) . Whole exome sequencing (WES), RNA-seq, and single-cell RNA-seq (scRNA-seq) were performed to analyze molecular differences. Drug screening targeting subtype-specific pathways was conducted to validate sequencing findings.  \nResults WES and RNA-seq confirmed that organoids retained parental tumor genetics and heterogeneity, distinct from paracancerous tissues. scRNA-seq revealed distinct cell populations in HCC, ICC, and CHC organoids. Lipid metabolism was enriched in HCC organoids; tumor migration pathways were upregulated in ICC organoids; and mitochondrial function was enhanced in CHC organoids. Rosuvastatin inhibited HCC growth by targeting lipid metabolism, while pemigatinib reduced ICC malignancy by suppressing epithelial-mesenchymal transition. Regorafenib impaired mitochondrial function in CHC organoids, slowing progression.  \nConclusions PLC-derived organoids serve as robust tools for biomarker discovery and drug screening. scRNA-seq elucidates inter- and intra-tumoral heterogeneity, offering insights for precision therapy in liver cancer. This model advances personalized treatment strategies for diverse PLC subtypes.  \nKeywords Primary liver cancer · Organoids · Whole exome sequencing · RNA sequencing · Single-cell RNA sequencing  \n1 Introduction  \nPrimary liver cancer (PLC), the second leading cause of global cancer-related mortality, arises from multifactorial etiologies including chronic hepatic injury, sustained inflammatory states, alcohol abuse, and parasitic infections. Alarmingly, its incidence has surged in parallel with escalating metabolic comorbidities such as diabetes and obesity  \nShipeng Dai, Jian Wu, Yue Chai and Zhouxiao Li contributed equally to this work.  \nExtended author information available on the last page of the article  \n[1] . Hepatocellular carcinoma (HCC, ~ 80%) and intrahepatic cholangiocarcinoma (ICC, ~ 15%) dominate PLC histopathology [2], while combined hepatocellular-cholangiocarcinoma (CHC), a rare biphenotypic malignancy (0.4–14.2%) exhibiting dual hepatobiliary differentiation-is distinguished by aggressive progression and dismal survival outcomes [3, 4] . Current therapeutic paradigms remain suboptimal: surgical resection offers limited survival benefits  \n1 3  \nfor advanced PLC, and CHC specific treatment guidelines are conspicuously absent [5] . This underscores an urgent need to elucidate CHC’s molecular drivers for biomarker discovery, diagnostic refinement, and targeted therapy development. Notably, while HCC and ICC demonstrate discrete histomorphological and molecular signatures enabling clear classification, CHC’s overlapping features necessitate personalized management strategies tailored to individual tumor biology [6] .  \nAlthough genomic landscapes of HCCand ICC have been extensively mapped through large-scale sequencing initiatives, CHC remains enigmatic due to sparse exome-le","cbCaii2vzBNJyfG6","https://ap.wps.com/l/cbCaii2vzBNJyfG6","pdf",11642599,"English","# Abstract\n# Introduction\n## Primary liver cancer background\n## Limitations of existing models\n## Rationale for organoids\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What organoid models were established in this study?\",\"answer\":\"Primary liver cancer organoids were generated from three major subtypes: HCC, ICC, and CHC, derived from 11 patients.\"},{\"question\":\"Which sequencing methods were used to characterize molecular differences?\",\"answer\":\"Whole exome sequencing (WES), RNA-seq, and single-cell RNA-seq (scRNA-seq) were used to analyze genetic and cellular heterogeneity.\"},{\"question\":\"How were subtype-specific drugs validated in the organoid system?\",\"answer\":\"Drug screening targeting pathways specific to each subtype was performed to confirm sequencing-based therapeutic vulnerabilities, such as rosuvastatin for HCC and pemigatinib for ICC.\"}]","Single-cell transcriptomic mapping of patient-derived primary liver cancer organoids reveals molecular subtypes and guides precision drug targeting | PDF",1790148798,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9e8212f15959768c9d9ed1006d1f5f8.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/179bc4f2837bc33d8b0a6ae7993c2f59.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70145522176d8e9a2d0270bafbc0d11a.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e65af75b999366ef2a1009896a269b7.webp",980,1301]